Association of Galectin-3 and Soluble ST2, and Their Changes, with Echocardiographic Parameters and Development of Heart Failure After ST-Segment Elevation Myocardial Infarction

Overview

Journal Dis Markers

Publisher Wiley

Specialty Biochemistry

Date 2019 Nov 6

PMID 31687050

Citations 7

Authors

Agata Tyminska

Agnieszka Kaplon-Cieslicka

Krzysztof Ozieranski

Monika Budnik

Anna Wancerz

Piotr Sypien

Michal Peller

Pawel Balsam

Grzegorz Opolski

Krzysztof J Filipiak

Affiliations

Soon will be listed here.

Abstract

Purpose: To investigate the association of galectin-3 (Gal-3) and soluble ST2 (sST2) and their follow-up changes with the development of heart failure (HF) and echocardiographic parameters of HF (ejection fraction, atrial and ventricular size, left ventricular hypertrophy, e', and E/e') in patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (pPCI).

Methods: A prospective, observational study, BIOSTRAT (Biomarkers for Risk Stratification After STEMI), enrolled 117 patients between October 2014 and April 2017. Gal-3 and sST2 serum collection and echocardiography were performed twice (during index hospitalization and on a control visit at one-year follow-up). The primary endpoint was HF onset at one-year follow-up. Secondary assessments included associations of biomarker concentration with echocardiographic indices of systolic and diastolic dysfunction at baseline and at one year.

Results: Mean baseline concentrations of Gal-3 and sST2 (7.5 and 26.4 ng/mL, respectively) were significantly increased at one-year follow-up (8.5 ng/mL and < 0.001 and 31.4 ng/mL and = 0.001, respectively). Patients who reached the primary endpoint (50 patients (48%)) had significantly higher baseline concentrations of both biomarkers and a higher Gal-3 level at one year compared to patients who did not. Both Gal-3 and sST2 were predictors of the primary endpoint in univariate logistic regression analysis, but only Gal-3 remained significant in multivariate analysis. There was no clear association between both biomarkers and echocardiographic parameters.

Conclusions: Baseline, but not one-year, changes of Gal-3 and sST2 concentrations may be useful for risk stratification after STEMI. However, only Gal-3 was the independent predictor of HF development at one-year observation. This trial is registered with NCT03735719.

Citing Articles

Short-term predictive value of sST2 in patients with STEMI following primary PCI: a prospective observational study.

Huang S, Yu L, Sun G, Zhang Z BMC Cardiovasc Disord. 2025; 25(1):21.

PMID: 39819309 PMC: 11737151. DOI: 10.1186/s12872-025-04488-z.

Soluble suppression of tumorigenicity 2 associated with microvascular obstruction in patients with ST-segment elevation myocardial infarction.

Du X, Liu J, Zhou J, Ren Y, Gul N, Chen L BMC Cardiovasc Disord. 2024; 24(1):691.

PMID: 39614185 PMC: 11607795. DOI: 10.1186/s12872-024-04364-2.

Understanding Galectin-3's Role in Diastolic Dysfunction: A Contemporary Perspective.

Hao W, Cheng C, Liu J, Chen H, Chen J, Cheng T Life (Basel). 2024; 14(7).

PMID: 39063659 PMC: 11277993. DOI: 10.3390/life14070906.

Comprehensive Quality Analysis of Conventional and Novel Biomarkers in Diagnosing and Predicting Prognosis of Coronary Artery Disease, Acute Coronary Syndrome, and Heart Failure, a Comprehensive Literature Review.

Abubakar M, Irfan U, Abdelkhalek A, Javed I, Khokhar M, Shakil F J Cardiovasc Transl Res. 2024; 17(6):1258-1285.

PMID: 38995611 DOI: 10.1007/s12265-024-10540-8.

Association of soluble suppression of tumorigenicity 2 protein with new-onset atrial fibrillation in patients with acute ST-segment elevation myocardial infarction undergoing primary PCI.

Zhao T, Pan T, Yang Y, Pei X, Wang Y Front Cardiovasc Med. 2023; 10:1207219.

PMID: 37808879 PMC: 10551440. DOI: 10.3389/fcvm.2023.1207219.

References

Minana G, Nunez J, Bayes-Genis A, Revuelta-Lopez E, Rios-Navarro C, Nunez E . ST2 and left ventricular remodeling after ST-segment elevation myocardial infarction: A cardiac magnetic resonance study. Int J Cardiol. 2018; 270:336-342. DOI: 10.1016/j.ijcard.2018.06.073. View

Sabatine M, Morrow D, Higgins L, Macgillivray C, Guo W, Bode C . Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation. 2008; 117(15):1936-44. PMC: 4273564. DOI: 10.1161/CIRCULATIONAHA.107.728022. View

Bayes-Genis A, De Antonio M, Vila J, Penafiel J, Galan A, Barallat J . Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3. J Am Coll Cardiol. 2013; 63(2):158-66. DOI: 10.1016/j.jacc.2013.07.087. View

Sutton M, Sharpe N . Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation. 2000; 101(25):2981-8. DOI: 10.1161/01.cir.101.25.2981. View

Sanchez-Mas J, Lax A, Asensio-Lopez M, Palacio M, Caballero L, Garrido I . Galectin-3 expression in cardiac remodeling after myocardial infarction. Int J Cardiol. 2014; 172(1):e98-e101. DOI: 10.1016/j.ijcard.2013.12.129. View

Grandin E, Jarolim P, Murphy S, Ritterova L, Cannon C, Braunwald E . Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22. Clin Chem. 2011; 58(1):267-73. DOI: 10.1373/clinchem.2011.174359. View

Vittinghoff E, McCulloch C . Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol. 2006; 165(6):710-8. DOI: 10.1093/aje/kwk052. View

Januzzi J, Mebazaa A, Di Somma S . ST2 and prognosis in acutely decompensated heart failure: the International ST2 Consensus Panel. Am J Cardiol. 2015; 115(7 Suppl):26B-31B. DOI: 10.1016/j.amjcard.2015.01.037. View

van der Velde A, Lexis C, Meijers W, Van Der Horst I, Lipsic E, Dokter M . Galectin-3 and sST2 in prediction of left ventricular ejection fraction after myocardial infarction. Clin Chim Acta. 2015; 452:50-7. DOI: 10.1016/j.cca.2015.10.034. View

10.

Szadkowska I, Wlazel R, Migala M, Szadkowski K, Zielinska M, Paradowski M . The association between galectin-3 and clinical parameters in patients with first acute myocardial infarction treated with primary percutaneous coronary angioplasty. Cardiol J. 2013; 20(6):577-82. DOI: 10.5603/CJ.2013.0157. View

11.

Steg P, James S, Atar D, Badano L, Blomstrom-Lundqvist C, Borger M . ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012; 33(20):2569-619. DOI: 10.1093/eurheartj/ehs215. View

12.

Tsai T, Sung P, Chang L, Sun C, Yeh K, Chung S . Value and level of galectin-3 in acute myocardial infarction patients undergoing primary percutaneous coronary intervention. J Atheroscler Thromb. 2012; 19(12):1073-82. DOI: 10.5551/jat.12856. View

13.

Sygitowicz G, Tomaniak M, Filipiak K, Koltowski L, Sitkiewicz D . Galectin-3 in Patients with Acute Heart Failure: Preliminary Report on First Polish Experience. Adv Clin Exp Med. 2016; 25(4):617-23. DOI: 10.17219/acem/60527. View

14.

Lang R, Badano L, Mor-Avi V, Afilalo J, Armstrong A, Ernande L . Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015; 16(3):233-70. DOI: 10.1093/ehjci/jev014. View

15.

Ghorbani A, Bhambhani V, Christenson R, Meijers W, de Boer R, Levy D . Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes. J Am Coll Cardiol. 2018; 72(25):3246-3254. PMC: 6516745. DOI: 10.1016/j.jacc.2018.09.076. View

16.

Ponikowski P, Voors A, Anker S, Bueno H, Cleland J, Coats A . 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special.... Eur J Heart Fail. 2016; 18(8):891-975. DOI: 10.1002/ejhf.592. View

17.

van der Velde A, Meijers W, Ho J, Brouwers F, Rienstra M, Bakker S . Serial galectin-3 and future cardiovascular disease in the general population. Heart. 2016; 102(14):1134-41. PMC: 5226848. DOI: 10.1136/heartjnl-2015-308975. View

18.

van Vark L, Lesman-Leegte I, Baart S, Postmus D, Pinto Y, Orsel J . Prognostic Value of Serial ST2 Measurements in Patients With Acute Heart Failure. J Am Coll Cardiol. 2017; 70(19):2378-2388. DOI: 10.1016/j.jacc.2017.09.026. View

19.

Tomaniak M, Sygitowicz G, Filipiak K, Blaszczyk O, Koltowski L, Gasecka A . Dysregulations of miRNAs and galectin-3 may underlie left ventricular dilatation in patients with systolic heart failure. Kardiol Pol. 2018; 76(6):1012-1014. DOI: 10.5603/KP.2018.0118. View

20.

Balsam P, Ozieranski K, Kaplon-Cieslicka A, Borodzicz S, Tyminska A, Peller M . Differences in clinical characteristics and 1-year outcomes of hospitalized patients with heart failure in ESC-HF Pilot and ESC-HF-LT registries. Pol Arch Intern Med. 2019; 129(2):106-116. DOI: 10.20452/pamw.4418. View